

Intensified Biomanufacturing Technologies

Building capacity for AAV and lentiviral vector production







ENHANCED UPSTREAM PROCESSING OF VIRAL VECTORS

A novel single-use, high-density bioreactor delivering reproducible and scalable production.




INTEGRATED & COST-EFFECTIVE VIRAL VECTOR PRODUCTION

Combining process intensification, automation and chaining to reduce footprint, capital and operational costs.

Intensified fixed-bed bioreactor

The scale-X bioreactor features a novel structured fixed-bed design alternating treated spiral-wound micro-fabric and spacer netting for:

- » Rapid and homogeneous cell entrapment:
- » Homogeneous media flow




Viral production and harvest

The scale-X fixed-bed bioreactor is chained with in-line product concentration for intensified cell culture and viral production delivering a concentrated harvest.

Formulation

Integrated formulation sequence for a complete solution from cell culture to drug substance preparation.

and nutrients availability.




[hydro] $[2.4 \, \text{m}^2]$

[carbo] [10-30 m²]



[nitro] [200-600 m²]



Scalable by design

- » Constant linear velocity of fluids and homogeneous cell distribution throughout the fixed-bed ensure reproducible performance at all scales;
- » Comprehensive portfolio features solutions for R&D, clinical and commercial scale production.

Scalable technology

» Seamless transitions through process development, clinical validation and commercial manufacture

High productivity

» Offering the highest throughput per cleanroom surface compared with currently available technologies

Cost-effective

» Significant operating costs savings across the different stages of the product lifecycle


Purification

Integrated and automated purification system using multicolumn chromatography to:

- » Increase resin utilization;
- » Reduce processing times;
- » Minimize surge tanks size.

A scalable roadmap to commercial success


The scale-X fixed-bed bioreactor portfolio enables a seamless transition from R&D to clinical development and commercial manufacture while minimizing process changes.



High capacity over a low footprint


The NevoLine platform features intensified manufacturing chained into a continuous, automated process to drastically decrease facility footprint and deliver:

- A scalable solution with high productivity
 - » Up to 20-fold higher productivity (vg/m² of cleanroom) compared to existing technologies
- An "all in one" solution compatible with modular facility design
 - » Rapid deployment in a POD or modular format in new or existing facility



Streamlined development with drastic savings

The NevoLine production platform drastically decreases COGs through reduction of key consumables and reagents, delivering significant savings for commercial-scale manufacture.



Assumptions

Extracellular product
Annual AAV demand: 1E+18vg/year